sv8
As filed with the Securities and Exchange Commission on January 31, 2011
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
VANDA PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
03-0491827 |
(State or other jurisdiction of
incorporation or organization)
|
|
(IRS Employer
Identification No.) |
9605 Medical Center Drive
Suite 300
Rockville, Maryland 20850
(Address of principal executive offices) (Zip Code)
VANDA PHARMACEUTICALS INC. 2006 EQUITY INCENTIVE PLAN
(Full title of the Plan)
Mihael H. Polymeropoulos, M.D.
Chief Executive Officer
Vanda Pharmaceuticals Inc.
9605 Medical Center Drive
Suite 300
Rockville, Maryland 20850
(Name and address of agent for service)
(240) 599-4500
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the
Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer þ
|
|
Non-accelerated filer o
(Do not check if a smaller
reporting company)
|
|
Smaller reporting company o |
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed Maximum |
|
|
Proposed Maximum |
|
|
|
|
|
|
|
|
Amount to be |
|
|
Offering Price per |
|
|
Aggregate Offering |
|
|
Amount of |
|
|
Title of Securities to be Registered |
|
|
Registered(1) |
|
|
Share(2) |
|
|
Price(2) |
|
|
Registration Fee |
|
|
Stock Options and Common Stock, $0.001 par value |
|
|
1,121,655 shares |
|
|
$7.84 |
|
|
$8,793,775.20 |
|
|
$1,020.96 |
|
|
|
|
|
(1) |
|
This Registration Statement shall also cover any additional shares of Common Stock which become
issuable under the 2006 Equity Incentive Plan by reason of any stock dividend, stock split,
recapitalization or other similar transaction effected without the receipt of consideration which
results in an increase in the number of the outstanding shares of Common Stock of Vanda
Pharmaceuticals Inc. Includes rights to purchase shares of the registrants Series A Junior
Participating Preferred Stock pursuant to the Rights Agreement dated September 25, 2008,
as amended. No separate consideration is paid for these rights and, as a result, the registration
fee for these rights is included in the fee for the Stock Options and Common Stock. |
|
(2) |
|
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to
Rule 457(c) and (h)(1) under the Securities Act of 1933, as amended. The offering price per share
and aggregate offering price for the unissued stock options and shares of Common Stock are based
upon the average of the high and low prices of the Registrants common stock as reported on The
NASDAQ Global Market on January 25, 2011. |
PART II
Information Required in the Registration Statement
Item 3. Incorporation of Documents by Reference
Vanda Pharmaceuticals Inc. (the Registrant) hereby incorporates by reference into this
Registration Statement the following documents previously filed with the Securities and Exchange
Commission (the SEC):
|
(a) |
|
The Registrants Annual Report on Form 10-K filed with the SEC for the fiscal
year ended December 31, 2009; |
|
|
(b) |
|
(1) The Registrants Quarterly Reports on Form 10-Q filed with the SEC for the
fiscal quarters ended March 31, 2010, June 30, 2010 and September 30, 2010; |
|
|
(2) |
|
The Registrants Current Reports on Form 8-K filed with the SEC on January 11,
2010, March 10, 2010, March 25, 2010, April 19, 2010, April 20, 2010, June 7, 2010,
July 1, 2010, July 9, 2010, November 12, 2010 and December 17, 2010, in each case
only to the extent filed and not furnished; |
|
|
(c) |
|
The description of the Registrants outstanding Common Stock contained in the
Registrants Registration Statement No. 000-51863 on Form 8-A filed with the SEC on
March 28, 2006, pursuant to Section 12 of the Securities Exchange Act of 1934, as
amended (the 1934 Act), including any amendment or report filed for the purpose of
updating such description; and |
|
|
(d) |
|
The description of the Registrants Rights to Purchase Series A Junior
Participating Preferred Stock contained in the Registrants Registration Statement No.
001-34186 on Form 8-A filed with the SEC on September 25, 2008, pursuant to Section 12
of the 1934 Act, including any amendment or report filed for the purpose of updating
such description. |
All reports and definitive proxy or information statements filed pursuant to Section 13(a),
13(c), 14 or 15(d) of the 1934 Act after the date of this Registration Statement and prior to the
filing of a post-effective amendment which indicates that all securities offered hereby have been
sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated
by reference into this Registration Statement and to be a part hereof from the date of filing of
such documents. Any statement contained in a document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded for purposes of this Registration
Statement to the extent that a statement contained herein, or in any other subsequently filed
document that also is or is deemed to be incorporated by reference herein, modifies or supersedes
such statement.
Item 4. Description of Securities
Not applicable.
Item 5. Interests of Named Experts and Counsel
Not applicable.
Item 6. Indemnification of Directors and Officers
The Registrant is incorporated under the laws of the State of Delaware. Section 145 of the
Delaware General Corporation Law authorizes a court to award or a corporations Board of Directors
to grant indemnification to directors and officers in terms sufficiently broad to permit such
indemnification under certain circumstances for liabilities (including reimbursement for expenses
incurred) arising under the Securities Act of 1933, as amended (the 1933 Act). The Registrants
Bylaws provide for indemnification of its directors and officers to the maximum extent permitted by
the Delaware General Corporation Law. The Registrants Certificate of Incorporation provides that,
pursuant to Delaware law, its directors shall not be liable for monetary damages for breach of
their fiduciary duty as directors to the Registrant and its stockholders. This provision in the
Certificate of Incorporation does not eliminate the fiduciary duty of the directors, and, in
appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary
relief will remain available under Delaware law. In addition, each director will continue to be
subject to liability for breach of the directors duty of loyalty to the Registrant for acts or
II-1
omissions not in good faith or involving intentional misconduct, for knowing violations of law, for
actions leading to improper
personal benefit to the director and for payment of dividends or approval of stock repurchases
or redemptions that are unlawful under Delaware law. The provision also does not affect a
directors responsibilities under any other law, such as the federal securities laws or state or
federal environmental laws. The Registrant has entered into Indemnification Agreements with its
directors and officers. The Indemnification Agreements provide the Registrants directors and
officers with further indemnification to the maximum extent permitted by the Delaware General
Corporation Law.
Item 7. Exemption from Registration Claimed
Not applicable.
Item 8. Exhibits
|
|
|
Exhibit Number |
|
Description |
4.1
|
|
Form of Amended and Restated Certificate of Incorporation of the Registrant
(filed as Exhibit 3.8 to Amendment No. 2 to the Registrants Registration
Statement on Form S-1 (File No. 333-130759), as filed on March 17, 2006, and
incorporated herein by reference) |
|
|
|
4.2
|
|
Second Amended and Restated Bylaws of the Registrant, as amended and restated on
December 16, 2008 (filed as Exhibit 3.11 to the Registrants current report on
Form 8-K (File No. 001-34186) as filed on December 17, 2008 and incorporated
herein by reference) |
|
|
|
4.3
|
|
Specimen certificate representing the common stock of the Registrant (filed as
Exhibit 4.4 to Amendment No. 2 to the Registrants Registration Statement on
Form S-1 (File No. 333-130759), as filed on March 17, 2006, and incorporated
herein by reference) |
|
|
|
4.4
|
|
Form of Certificate of Designation of Series A Junior Participating Preferred
Stock (filed as Exhibit 3.10 to the Registrants current report on Form 8-K
(File No. 001-34186) as filed on September 25, 2008 and incorporated herein by
reference) |
|
|
|
4.5
|
|
Rights Agreement, dated as of September 25, 2008, between the Registrant and
American Stock Transfer & Trust Company, LLC, as Rights Agent (filed as Exhibit
4.5 to the Registrants current report on Form 8-K (File No. 001-34186) as filed
on September 25, 2008 and incorporated herein by reference) |
|
|
|
4.6
|
|
Amendment to Rights Agreement, dated as of December 22, 2009, between the
Registrant and American Stock Transfer & Trust Company, LLC, as Rights Agent
(filed as Exhibit 4.6 to the Registrants current report on Form 8-K (File No.
001-34186) as filed on December 22, 2009 and incorporated herein by reference) |
|
|
|
4.7
|
|
2004 Securityholder Agreement (as amended) (filed as Exhibit 4.1 to the
Registrants Registration Statement on Form S-1 (File No. 333-130759), as
originally filed on December 29, 2005, and incorporated herein by reference) |
|
|
|
5.1
|
|
Opinion and consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian
LLP |
|
|
|
23.1
|
|
Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
(included in Exhibit 5) |
|
|
|
23.2
|
|
Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting
Firm |
|
|
|
24
|
|
Power of Attorney. Reference is made to page II-5 of this Registration Statement |
|
|
|
99.1
|
|
Vanda Pharmaceuticals Inc. 2006 Equity Incentive Plan, as amended and restated
effective as of June 3, 2010 (filed as Exhibit 10.38 to the Registrants current
report on Form 8-K (File No. 001-34186) as filed on June 7, 2010 and
incorporated herein by reference) |
II-2
Item 9. Undertakings
A. The undersigned Registrant hereby undertakes: (1) to file, during any period in which
offers or sales are being made, a post-effective amendment to this Registration Statement (i) to
include any prospectus required by Section 10(a)(3) of the 1933 Act, (ii) to reflect in the
prospectus any facts or events arising after the effective date of this Registration Statement (or
the most recent post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in this Registration Statement and
(iii) to include any material information with respect to the plan of distribution not previously
disclosed in this Registration Statement or any material change to such information in this
Registration Statement; provided, however, that clauses (1)(i) and (1)(ii) shall not apply
if the information required to be included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or
Section 15(d) of the 1934 Act that are incorporated by reference in this Registration Statement;
(2) that for the purpose of determining any liability under the 1933 Act each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered
therein and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof and (3) to remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the Registrants
2006 Equity Incentive Plan.
B. The undersigned Registrant hereby undertakes that, for purposes of determining any
liability under the 1933 Act, each filing of the Registrants annual report pursuant to Section
13(a) or Section 15(d) of the 1934 Act that is incorporated by reference in this Registration
Statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
C. Insofar as indemnification for liabilities arising under the 1933 Act may be permitted to
directors, officers or controlling persons of the Registrant pursuant to the indemnification
provisions summarized in Item 6 or otherwise, the Registrant has been advised that, in the opinion
of the SEC, such indemnification is against public policy as expressed in the 1933 Act, and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the Registrant of expenses incurred or paid by a director, officer or
controlling person of the Registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the 1933 Act and will be governed by
the final adjudication of such issue.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland on this
31st day of January, 2011.
|
|
|
|
|
|
VANDA PHARMACEUTICALS INC.
|
|
|
By: |
/s/ Mihael H. Polymeropoulos
|
|
|
|
Mihael H. Polymeropoulos, M.D. |
|
|
|
Chief Executive Officer |
|
II-4
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS:
That the undersigned officers and directors of Vanda Pharmaceuticals Inc., a Delaware
corporation, do hereby constitute and appoint Mihael H. Polymeropoulos, M.D. and James P. Kelly,
and either of them, the lawful attorneys-in-fact and agents with full power and authority to do any
and all acts and things and to execute any and all instruments which said attorneys and agents, and
either one of them, determine may be necessary or advisable or required to enable said corporation
to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements
of the Securities and Exchange Commission in connection with this Registration Statement. Without
limiting the generality of the foregoing power and authority, the powers granted include the power
and authority to sign the names of the undersigned officers and directors in the capacities
indicated below to this Registration Statement, to any and all amendments, both pre-effective and
post-effective, and supplements to this Registration Statement, and to any and all instruments or
documents filed as part of or in conjunction with this Registration Statement or amendments or
supplements thereof, and each of the undersigned hereby ratifies and confirms all that said
attorneys and agents, or either one of them, shall do or cause to be done by virtue hereof. This
Power of Attorney may be signed in several counterparts.
IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date
indicated. Pursuant to the requirements of the Securities Act of 1933, as amended, this
Registration Statement has been signed below by the following persons in the capacities and on the
dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
/s/ Mihael H. Polymeropoulos, M.D.
Mihael H. Polymeropoulos, M.D.
|
|
President, Chief Executive Officer and
Director
(Principal Executive Officer)
|
|
January 31, 2011 |
|
|
|
|
|
/s/ James P. Kelly
James P. Kelly
|
|
Chief Financial Officer and Treasurer
(Principal Financial Officer and
Principal Accounting Officer)
|
|
January 31, 2011 |
|
|
|
|
|
/s/ Howard H. Pien
Howard H. Pien
|
|
Director and Chairman of Board
|
|
January 31, 2011 |
|
|
|
|
|
/s/ Richard W. Dugan
Richard W. Dugan
|
|
Director
|
|
January 31, 2011 |
|
|
|
|
|
/s/ Steven K. Galson, M.D.
Steven K. Galson, M.D.
|
|
Director
|
|
January 31, 2011 |
|
|
|
|
|
/s/ Argeris N. Karabelas, Ph.D.
Argeris N. Karabelas, Ph.D.
|
|
Director
|
|
January 31, 2011 |
|
|
|
|
|
/s/ Vincent J. Milano
Vincent J. Milano
|
|
Director
|
|
January 31, 2011 |
|
|
|
|
|
/s/ H. Thomas Watkins
H. Thomas Watkins
|
|
Director
|
|
January 31, 2011 |
II-5
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
4.1
|
|
Form of Amended and Restated Certificate of Incorporation of the Registrant
(filed as Exhibit 3.8 to Amendment No. 2 to the Registrants Registration
Statement on Form S-1 (File No. 333-130759), as filed on March 17, 2006, and
incorporated herein by reference) |
|
|
|
4.2
|
|
Second Amended and Restated Bylaws of the Registrant, as amended and restated on
December 16, 2008 (filed as Exhibit 3.11 to the Registrants current report on
Form 8-K (File No. 001-34186) as filed on December 17, 2008 and incorporated
herein by reference) |
|
|
|
4.3
|
|
Specimen certificate representing the common stock of the Registrant (filed as
Exhibit 4.4 to Amendment No. 2 to the Registrants Registration Statement on
Form S-1 (File No. 333-130759), as filed on March 17, 2006, and incorporated
herein by reference) |
|
|
|
4.4
|
|
Form of Certificate of Designation of Series A Junior Participating Preferred
Stock (filed as Exhibit 3.10 to the Registrants current report on Form 8-K
(File No. 001-34186) as filed on September 25, 2008 and incorporated herein by
reference) |
|
|
|
4.5
|
|
Rights Agreement, dated as of September 25, 2008, between the Registrant and
American Stock Transfer & Trust Company, LLC, as Rights Agent (filed as Exhibit
4.5 to the Registrants current report on Form 8-K (File No. 001-34186) as filed
on September 25, 2008 and incorporated herein by reference) |
|
|
|
4.6
|
|
Amendment to Rights Agreement, dated as of December 22, 2009, between the
Registrant and American Stock Transfer & Trust Company, LLC, as Rights Agent
(filed as Exhibit 4.6 to the Registrants current report on Form 8-K (File No.
001-34186) as filed on December 22, 2009 and incorporated herein by reference) |
|
|
|
4.7
|
|
2004 Securityholder Agreement (as amended) (filed as Exhibit 4.1 to the
Registrants Registration Statement on Form S-1 (File No. 333-130759), as
originally filed on December 29, 2005, and incorporated herein by reference) |
|
|
|
5.1
|
|
Opinion and consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian
LLP |
|
|
|
23.1
|
|
Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
(included in Exhibit 5) |
|
|
|
23.2
|
|
Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting
Firm |
|
|
|
24
|
|
Power of Attorney. Reference is made to page II-5 of this Registration Statement |
|
|
|
99.1
|
|
Vanda Pharmaceuticals Inc. 2006 Equity Incentive Plan, as amended and restated
effective as of June 3, 2010 (filed as Exhibit 10.38 to the Registrants current
report on Form 8-K (File No. 001-34186) as filed on June 7, 2010 and
incorporated herein by reference) |
exv5w1
EXHIBIT 5.1
January 31, 2011
Vanda Pharmaceuticals Inc.
9605 Medical Center Drive, Suite 300
Rockville, Maryland 20850
|
Re: |
|
Vanda Pharmaceuticals Inc. Registration Statement
on Form S-8 for 1,121,655 Shares of Common Stock |
Ladies and Gentlemen:
We refer to your registration statement on Form S-8 (the Registration Statement) under the
Securities Act of 1933, as amended (the Act) in connection with the registration of 1,121,655
shares of Common Stock (the Shares) of Vanda Pharmaceuticals Inc. (the Company) issuable in the
aggregate under the Companys 2006 Equity Incentive Plan (the Plan).
As your counsel, we have examined such matters of fact and questions of law as we have deemed
necessary in order to render the opinion set forth herein. In connection with our opinion
expressed below, we have relied as to certain factual matters on information obtained from public
officials, officers of the Company and other sources believed by us to be responsible. We express
no opinion as to matters governed by any laws other than the laws of the Delaware General
Corporation Law and the federal laws of the United States.
Based upon and subject to the foregoing, we advise you that, in our opinion, when the Shares have
been issued and sold pursuant to the applicable provisions of the Plan, and in accordance with the
Registration Statement, such Shares will be validly issued, fully paid and nonassessable shares of
the Companys Common Stock.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In
giving such consent, we do not thereby admit that we are in the category of persons whose consent
is required under Section 7 of the Act.
|
|
|
|
|
|
Very truly yours,
|
|
|
/s/ Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
|
|
|
|
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP |
|
|
|
|
|
exv23w2
EXHIBIT 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of
our report dated March 15, 2010 relating to the financial statements and the effectiveness of
internal control over financial reporting, which appears in Vanda Pharmaceuticals Inc.s Annual
Report on Form 10-K for the year ended December 31, 2009.
/s/ PricewaterhouseCoopers LLP
Baltimore, MD
January 31, 2011